Creso Pharma is raising $5 million through a placement wherein it will offer new shares for 6.9 cents apiece.
At the close of trading, the Creso Pharma share price was 6.9 cents, having tumbled 10.39%.
Let’s take a look at what the ASX cannabis share plans to do with its raised cash.
What sent this ASX cannabis share plummeting?
ASX cannabis company Creso Pharma’s share price is falling after the company announced a placement to raise $5 million to help fund its expansion into the United States.
As part of the placement, involved investors will receive 1 free option for every share they purchase.
On top of that, the placement’s broker, EverBlu Capital, will also receive an option for every free option handed out.
The options will be exercisable at a price of 14 cents each on or before the 18-month anniversary of their issuing.
Creso Pharma non-executive director Adam Blumenthal has committed to purchasing around $318,250 worth of new shares as part of the placement. Blumenthal’s participation is subject to shareholder approval at a future general meeting.
The $5 million will be put towards the company’s expansion into the United States after it acquires Sierra Sage Herbs and Green Goo brand.
The cannabis company announced its acquisition to the ASX earlier this month, causing its share price to surge 5.8%.
Some of the funds raised through the placement will go towards product development and general working capital.
Speaking on the capital raise, Creso Pharma CEO and managing director, William Lay commented:
These funds will provide us with additional financial flexibility to advance our US-focused growth trajectory, progress a number of new product development initiatives, and explore new opportunities to unlock shareholder value.
The company remains very well positioned to capitalise on the global market for recreational cannabis, CBD products, and psychedelic treatments. We have a number of growth initiatives underway and look forward to providing additional updates as these materialise.
Creso Pharma share price snapshot
This year so far has been rough on the Creso Pharma share price.
It has fallen 15% since the start of the year. It’s also 60% lower than it was this time last year.